Relapsing-Remitting Multiple Sclerosis Clinical Trial
— SOLAROfficial title:
A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate the Efficacy of Vigantol® Oil as Add on Therapy in Subjects With Relapsing Remitting Multiple Sclerosis Receiving Treatment With 44mg Tiw of Rebif®
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone
supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated
with a higher risk of developing Multiple Sclerosis (MS), and it is known that up to 90% of
patients with Multiple Sclerosis have Vitamin D deficiency.
Rebif® is known to be an effective treatment for slowing down the progression of MS. The
purpose of this research trial is to evaluate if VigantOL® oil on top of Rebif® has any
benefit on the progression of MS compared to Rebif® and placebo.
Disease activity will be assessed by clinical examination and Magnetic Resonance Imaging
(MRI). The planned study treatment duration for each study participant is 48 weeks, and the
study consists of a total of 8 visits. Study participants who are already passed Week 48 at
the time of approval of Protocol Amendment 5 will have a study duration of 96 weeks and a
total of 12 visits.
During the study, the participant will undergo physical examination, neurological
assessments, safety assessments, blood tests and urinalysis (including pregnancy tests).
Status | Completed |
Enrollment | 232 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of a relapsing-remitting form of MS - Brain and/or spinal MRI with findings typical of MS - A first clinical event prior to Screening. - Disease activity - EDSS score of less than, or equal to 4.0 at Screening. - Currently treated with interferon-beta-1a 44mg (tiw) sc - Willingness and ability to comply with the protocol - Written informed consent Exclusion Criteria: - Pregnancy and lactation period - Any disease other than MS that could better explain signs and symptoms. - Complete transverse myelitis or bilateral optic neuritis. - Currently receiving or use at any time of monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone [ACTH]), B cell modulating therapies (e.g. RituxiMab or BelimuMab), total lymphoid irradiation or bone marrow transplantation. - Use of any cytokine other than interferon or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, or any investigational drug or experimental procedure - Use of oral or systemic corticosteroids or ACTH - Have abnormalities of Vitamin D related hormonal system other than low dietary intake or decreased sun exposure, i.e. primary hyperparathyroidism or granulomatous disorders. - Have an urine calcium/creatinine (mmol/mmol) ratio greater than 1.0 or hypercalcaemia - Are taking medications that influence Vitamin D metabolism other than corticosteroids, e.g., phenytoin, barbiturates, thiazide diuretics and cardiac glycosides. - Are taking more than 1000 IU (25 µg) of Vitamin D supplement daily. - Have conditions with increased susceptibility to hypercalcaemia, e.g., known arrhythmia or heart disease, treatment with Digitalis, or Hydrochlorothiazide and those who suffer from nephrolithiasis. - Have inadequate liver function - Moderate to severe renal impairment - Inadequate bone marrow reserve - History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (NYHA class 3 or 4). - History or presence of severe depression, history of suicide attempt, or current suicidal ideation. - Epilepsy or seizures not adequately controlled by treatment. - Current or past alcohol or drug abuse. - Any major medical or psychiatric illness (such as psychosis, bipolar disorder) that in the opinion of the Investigator could create undue risk to the subject or could affect adherence with the trial protocol. - Known contra-indication to treatment with vitamin D - Known hypersensitivity to interferon or its excipient(s) - Known hypersensitivity to gadolinium. - Any other condition that would prevent the subject from undergoing an MRI scan. - Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such. - Positive HIV, hepatitis C, or hepatitis B (HBsAg and HBc antibody) serology (test performed at screening). - Legal incapacity or limited legal capacity. - Another current autoimmune disease, except diabetes. - Have experienced a relapse within 30 days. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Research Site | Vienna | |
Denmark | Research Site | Esbjerg | |
Denmark | Research Site | Glostrup | |
Denmark | Research Site | Sønderborg | |
Denmark | Research Site | Vejle | |
Denmark | Research Site | Viborg | |
Estonia | Research Site | Tallinn | |
Finland | Research Site | Helsinki | |
Finland | Research Site | Turku | |
Germany | Research Site | Bad Neustadt / Saale | |
Germany | Research Site | Bamberg | |
Germany | Research Site | Berlin | |
Germany | Research Site | Erlangen | |
Germany | Research Site | Freiburg | |
Germany | Research Site | Hannover | |
Germany | Research Site | Köln | |
Germany | Research Site | Münster | |
Germany | Research Site | Regensburg | |
Germany | Research Site | Rostock | |
Italy | Research Site | Cefalu | |
Latvia | Research Site | Riga | |
Lithuania | Research Site | Kaunas | |
Netherlands | Research Site | Amsterdam | |
Netherlands | Research Site | Gouda | |
Netherlands | Research Site | Nieuwegein | |
Netherlands | Research Site | Rotterdam | |
Netherlands | Research Site | Sittard | |
Norway | Research Site | Bergen | |
Norway | Research Site | Lørenskog | |
Norway | Research Site | Tromsø | |
Portugal | Research Site | Amadora | |
Portugal | Research Site | Lisboa | |
Portugal | Research Site | Porto | |
Switzerland | Research Site | Bern | |
Switzerland | Research Site | Lausanne | |
Switzerland | Research Site | Lugano | |
Switzerland | Research Site | St. Gallen | |
Switzerland | Research Site | Zurich |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA |
Austria, Denmark, Estonia, Finland, Germany, Italy, Latvia, Lithuania, Netherlands, Norway, Portugal, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects with disease activity free status (no relapses, no EDSS progression and no new Gd-enhancing or T2 MRI lesions) at Week 48 | 48 weeks | No | |
Secondary | Percentage of relapse-free subjects at Week 48 | 48 Weeks | No | |
Secondary | Percentage of subjects free from any Expanded Disability Status Scale (EDSS) progression at Week 48 | 48 Weeks | No | |
Secondary | Time to confirmed EDSS progression | 48 Weeks | No | |
Secondary | Percentage of subjects free from confirmed EDSS progression at Week 48 | 48 Weeks | No | |
Secondary | Cumulative number of T1 gadolinium enhancing lesions at Week 48 | 48 Weeks | No | |
Secondary | Mean number of combined unique active (CUA) lesions per subject per scan at Week 48 | 48 Weeks | No | |
Secondary | Cumulative number of new combined unique active (CUA) lesions at Week 48 | 48 Weeks | No | |
Secondary | Mean change from baseline in the total volume of T2 lesions at Week 48 (T2 Burden of disease) | Total volume of T2 lesions will be assessed in mm^3 | Baseline and 48 Weeks | No |
Secondary | Percentage of subjects free from T1 gadolinium enhancing lesions at Week 48 | 48 Weeks | No | |
Secondary | Percentage of subjects free from new T1 hypointense lesions (black holes) at Week 48 | 48 Weeks | No | |
Secondary | Percentage of new T1 hypointense lesions (black holes) at Week 48 within the subgroup of new or enlarging non-enhancing T2 lesions | 48 Weeks | No | |
Secondary | Time to first documented relapse | 48 weeks | No | |
Secondary | Annualised relapse rate at Week 48 | 48 weeks | No | |
Secondary | Total number of reported relapses at all time points up to 48 weeks | up to 48 weeks | No | |
Secondary | Percentage of subjects treated with glucocorticoids due to relapses | 48 weeks | No | |
Secondary | Mean change from baseline in the total volume of T1 hypointense lesions at Week 48 | Baseline and 48 Weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|